Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 8/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 8/20 | 0.58 |
| ▸ | ADRB2 | P07550 | 7/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.58 |
| ▸ | ADRB1 | P08588 | 5/20 | 0.58 |
| ▸ | BLM | P54132 | 5/20 | 0.58 |
| ▸ | MEN1 | O00255 | 4/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.58 |
| ▸ | ADRB3 | P13945 | 4/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.58 |
| ▸ | APEX1 | P27695 | 3/20 | 0.58 |
| ▸ | RECQL | P46063 | 3/20 | 0.58 |
| ▸ | HPGD | P15428 | 3/20 | 0.58 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.58 |
| ▸ | DRD2 | P14416 | 3/20 | 0.58 |
| ▸ | ADRA1D | P25100 | 3/20 | 0.58 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.58 |
| ▸ | ADRA1B | P35368 | 3/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.58 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL521779 | 1.00 | MAPT (0.58) | MAPTTDP1ADRB2KDM4EADRB1 | |
| SCHEMBL17053665 | 0.87 | MAPT (0.56) | MAPTTDP1ADRB2KDM4EADRB1 | |
| SCHEMBL25100809 | 0.84 | TDP1 (0.53) | MAPTTDP1ADRB2KDM4EADRB1 | |
| SCHEMBL22971597 | 0.84 | MAPT (0.54) | MAPTTDP1ADRB2KDM4EADRB1 | |
| SCHEMBL328574 | 0.82 | TDP1 (0.51) | MAPTTDP1ADRB2KDM4EADRB1 | |
| SCHEMBL11184587 | 0.82 | ADRB2 (0.57) | TDP1ADRB2ADRB1TSHRCYP1A2 | |
| SCHEMBL31392613 | 0.81 | RAD52 (0.60) | MAPTTDP1ADRB2KDM4EADRB1 | |
| SCHEMBL23040663 | 0.81 | KDM4E (0.53) | MAPTTDP1ADRB2KDM4EADRB1 | |
| SCHEMBL23040664 | 0.81 | KDM4E (0.53) | MAPTTDP1ADRB2KDM4EADRB1 | |
| SCHEMBL9768101 | 0.80 | MAPT (0.49) | MAPTTDP1ADRB2KDM4EADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9964552-B2 | Mass spectrometric identification and/or quantitation of catecholamines using aminopyrazoles | DH TECHNOLOGIES DEVELOPMENT PTE. LTD. (SG) | 2018-05-08 | — | — | US | claimed |
| US-20160305969-A1 | MASS SPECTROMETRIC IDENTIFICATION AND/OR QUANTITATION OF CATECHOLAMINES USING AMINOPYRAZOLES | DH TECHNOLOGIES DEVELOPMENT PTE. LTD. (SG) | 2016-10-20 | — | — | US | claimed |
| EP-3063540-A1 | MASS SPECTROMETRIC IDENTIFICATION AND/OR QUANTITATION OF CATECHOLAMINES USING AMINOPYRAZOLES | DH Technologies Development PTE. Ltd. (SG) | 2016-09-07 | — | — | EP | claimed |
| CN-105659078-A | Mass spectrometric identification and/or quantitation of catecholamines using aminopyrazoles | DH科技发展私人贸易有限公司 | 2016-06-08 | — | — | CN | claimed |
| WO-2015063563-A1 | MASS SPECTROMETRIC IDENTIFICATION AND/OR QUANTITATION OF CATECHOLAMINES USING AMINOPYRAZOLES | DH TECHNOLOGIES DEVELOPMENT PTE. LTD. (SG) | 2015-05-07 | — | — | WO | claimed |
| US-20120029085-A1 | STABILIZATION OF QUINOL COMPOSITION SUCH AS CATECHOLAMINE DRUGS | MACKAY JON (US) | 2012-02-02 | — | — | US | claimed |
| US-20240074995-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FIRST WAVE BIO, INC. | 2024-03-07 | — | — | US | disclosed |
| US-11793777-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory response | FIRST WAVE BIO, INC. (US) | 2023-10-24 | — | — | US | disclosed |
| US-11744812-B2 | Methods of treatment | FIRST WAVE BIO, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| US-20230201143-A1 | METHODS OF TREATMENT | FIRST WAVE BIO, INC. | 2023-06-29 | — | — | US | disclosed |
| US-20230190684-A1 | METHODS OF TREATING COVID-19 WITH A NICLOSAMIDE COMPOUND | FIRST WAVE BIO, INC. | 2023-06-22 | — | — | US | disclosed |
| US-20230102999-A1 | DEUTERATED NICLOSAMIDE | FIRST WAVE BIO, INC. | 2023-03-30 | — | — | US | disclosed |
| WO-2023028350-A1 | THERAPEUTIC COMPOSITIONS AND RELATED METHODS | BOYCE THOMPSON INSTITUTE FOR PLANT RESEARCH, INC. (US) | 2023-03-02 | — | — | WO | disclosed |
| US-8163701-B2 | Prodrugs of active agents | SIGNATURE THERAPEUTICS, INC. (US) | 2012-04-24 | — | — | US | disclosed |
| US-20120029085-A1 | STABILIZATION OF QUINOL COMPOSITION SUCH AS CATECHOLAMINE DRUGS | MACKAY JON (US) | 2012-02-02 | — | — | US | disclosed |
| US-7927613-B2 | Pharmaceutical co-crystal compositions | UNIVERSITY OF SOUTH FLORIDA (US) | 2011-04-19 | — | — | US | disclosed |
| WO-2008139152-A1 | N-OXIDE-CONTAINING PHARMACEUTICAL COMPOUNDS | SENTINEL ONCOLOGY LIMITED (GB) | 2008-11-20 | — | — | WO | disclosed |
| EP-1928881-A2 | PRODRUGS OF ACTIVE AGENTS | Pharmacofore, Inc. (US) | 2008-06-11 | — | — | EP | disclosed |
| US-20070123468-A1 | Prodrugs of active agents | PHARMACOFORE, INC. | 2007-05-31 | — | — | US | disclosed |
| WO-2007022535-A2 | PRODRUGS OF ACTIVE AGENTS | PHARMACOFORE, INC. (US) | 2007-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240074995-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FH, CS, ECHS1 | MAPT 954/4885TDP1 1443/4885ADRB2 3795/4885 |
| US-20160305969-A1 | MASS SPECTROMETRIC IDENTIFICATION AND/OR QUANTITATION OF CATECHOLAMINES USING AMINOPYRAZOLES | AADAT, AASDHPPT, AANAT | MAPT 2854/4885TDP1 1064/4885ADRB2 73/4885 |
| US-20230190684-A1 | METHODS OF TREATING COVID-19 WITH A NICLOSAMIDE COMPOUND | ACE2, ACE, MME | MAPT 704/4885TDP1 4136/4885ADRB2 2647/4885 |
| US-11744812-B2 | Methods of treatment | ACE2, ACE, SI | MAPT 845/4885TDP1 3753/4885ADRB2 3018/4885 |
| US-20230201143-A1 | METHODS OF TREATMENT | ACE2, ACE, SI | MAPT 753/4885TDP1 3910/4885ADRB2 3495/4885 |
| US-20230102999-A1 | DEUTERATED NICLOSAMIDE | FH, IDH2, ECHS1 | MAPT 1112/4885TDP1 1453/4885ADRB2 2922/4885 |
| US-20120029085-A1 | STABILIZATION OF QUINOL COMPOSITION SUCH AS CATECHOLAMINE DRUGS | ADRA2C, ADRB2, ADRB1 | MAPT 984/4885TDP1 1679/4885ADRB2 2/4885 |
| US-20070123468-A1 | Prodrugs of active agents | PAICS, AADAC, NQO1 | MAPT 3235/4885TDP1 335/4885ADRB2 3261/4885 |
| US-11793777-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory response | FH, CS, ECHS1 | MAPT 971/4885TDP1 1471/4885ADRB2 3816/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.